Background: Medical staff often overlook or underestimate the presence or severity of cognitive dysfunction. The purpose of this study was to clarify the frequency, clinical indicators and predictors of cognitive dysfunction among newly diagnosed older patients with hematologic malignancy receiving first-line chemotherapy. Methods: Patients aged 65 years or over with a primary diagnosis of malignant lymphoma or multiple myeloma were consecutively recruited. Cognitive dysfunction was evaluated using the Mini-Mental State Examination (MMSE) twice: before starting chemotherapy (T1) and 1 month later (T2). Participants also underwent a comprehensive geriatric assessment at T1. Potential clinical indicators that were associated with cognitive dysfunction were explored via cross-sectional analysis at T1. Predictors of cognitive dysfunction at T2 were also investigated among patients without cognitive dysfunction at T1. Results: A total of 145 participants participated in the study; cognitive dysfunction at T1 was present in 20%. Multivariate analysis demonstrated that lower educational attainment and poorer instrumental activities of daily living were significant clinical indicators of cognitive dysfunction. Among 99 patients who did not have cognitive dysfunction at T1 and underwent cognitive assessment at T2, 7% developed dysfunction. Subjective perception of difficulty remembering at T1 was the only factor which significantly predicted new-onset cognitive dysfunction at T2. Conclusions: The prevalence rate of cognitive dysfunction was non-negligible among older patients with hematologic malignancy before and immediately after initial chemotherapy. Attention to the clinical indicators and predictors found in this study may provide facilitate the identification of cognitive dysfunction in patients with cancer.
Introduction
Aging is among the most important risk factors for cancer. The number of older patients with cancer continues to increase worldwide, as does the size of the older population. Japan has one of the highest longevity rates in the world, and 300 000 (81% of all cancer mortality) and 600 000 adults (70% of all cancer incidence) aged 65 years or older develop cancer and die from cancer in 2015, respectively, each year (1, 2) .
Cognitive dysfunction is also common in older Japanese populations. Over 24 million adults aged 60 years or older are estimated to suffer from dementia; this number is expected to increase to 42 million in 2020 (3) . As such, cognitive dysfunction is one of the most frequently encountered problems in geriatric oncology practice. Previous studies reported that the prevalence of cognitive dysfunction in cancer patients ranged from 10% to 69% (4) (5) (6) (7) (8) . This wide variation is due to differences in the populations investigated, definitions of cognitive dysfunction, and assessment methods used. Most previous studies did not focus on elderly cancer patients, included patients at different time points in the illness trajectory, or did not assess cognitive dysfunction using established assessment methods.
Cognitive dysfunction in cancer patients causes various problems, including impaired medical decision-making capacity (9) , impaired psychosocial functioning (10) , difficulty engaging in work and daily functions (11) , adherence to medical treatments (12) , deterioration of quality of life (13, 14) , caregiver burden (15) and patient survival (16) . Despite these negative impacts, it has been repeatedly reported that medical staff often overlook or underestimate the presence or severity of cognitive dysfunction (17) . It is therefore important to identify the useful clinical indicators and predictors of cognitive dysfunction.
To the best of our knowledge, no studies have investigated cognitive dysfunction in older patients with hematological cancer, likely because hematologic malignancy is rarer than solid carcinoma. Because the first line of the treatment of hematological malignancy in elderly cancer patients is chemotherapy which may influence on patients' cognitive function negatively, it is highly important to understand the levels of cognitive dysfunction before and after treatment. The purpose of this study was to clarify the frequency of cognitive dysfunction and identify clinical indicators and predictors of cognitive dysfunction among newly diagnosed older patients with hematologic malignancy receiving first-line chemotherapy.
Patients and methods

Study design and participants
This was a longitudinal, observational study. Recruitment of patients was conducted from September 2010 to March 2016. Eligibility criteria required participants were to be: inpatients who had been newly diagnosed with malignant lymphoma or multiple myeloma, 65 years of age or older, informed of the cancer diagnosis, intending to undergo chemotherapy and physically well enough to complete the survey questionnaire. Exclusion criteria were presence of clinically diagnosed severe mental or cognitive disorders and/or inability to understand Japanese.
The study was conducted with the approval of the Institutional Review Board and Ethics Committee of Nagoya City University Graduate School of Medical Sciences, Japan, and was conducted in accordance with the principles stated in the Declaration of Helsinki. Written consent was obtained from each eligible participant following a thorough explanation of the purpose and method of the study. If participants could not fully understand the content of the study protocol, both their oral consent and their surrogates' written consent were obtained.
Procedures
All potentially eligible participants were identified at the time of admission to the hospital (i.e. consecutive sampling) and assessed for eligibility before starting chemotherapy. Patients were then asked to complete the assessment of cognitive function at two time points: before starting chemotherapy (T1) and 1 month later (T2). Participants also underwent a comprehensive geriatric assessment (CGA) at T1. Briefly, the CGA (described in more detail below) is a multidimensional method used by geriatricians and oncologists to detect and evaluate multiple age-related problems and coordinate interventions.
Measurements
Cognitive dysfunction
The Mini-Mental State Examination (MMSE) was used to evaluate patients' cognitive function (18) . This scale assesses global cognitive function and is comprised of questions regarding orientation, shortand long-term memory, calculation ability and word recall. Total scores range from 0 to 30, with higher scores indicating better cognitive function. We applied a cut-off score of 23/24 to identify the presence of cognitive dysfunction (18) . The validity and reliability of the Japanese version of this scale has been previously established (19) . The following outcomes were evaluated to assess potential clinical and predictive factors of cognitive function.
Comprehensive geriatric assessment
The CGA consists of the following six domains assessed using tools validated in Japanese:
Activities of daily living (ADL) Patients' activities of daily living and mobility were assessed using the Barthel Index, which is one of the most commonly used instruments for assessing ADL (20) . Total scores range from 0 to 100, with higher scores indicating more independence. We applied a cut-off score of 90/91.
Instrumental activities of daily living (IADL) The Lawton IADL scale was used to assess instrumental activities of daily living (21) . Total scores range from 0 to 8. Due to the differing social roles of men and women in Japan, different cut-off scores were applied for men (4/5) and women (7/8) .
Comorbidity Patients' co-morbidities were scored by attending physicians using the Cumulative Illness Rating Scale for Geriatrics (CIRS-G) (22) . Each comorbidity was assigned to one of 14 organ systems and rated from 0 (no comorbidity) to 4 (extremely severe comorbidity). We defined presence of comorbidity as having one or more Grade 3 (severe/constant significant disability/'uncontrollable' chronic problems) or Grade 4 comorbidity (hematological comorbidities were not investigated).
Nutritional status Body mass index (kg/m 2 ) was calculated to assess nutritional status. A cut-off score of 18.5 was used in this study.
Polypharmacy The number of medications currently taken by each subject was investigated based on a review of medical records. Taking five or more medications was defined as polypharmacy.
Depression Presence or absence of depression was assessed using the Patient Health Questionnaire-9 (PHQ-9) (23, 24) . PHQ-9 consists of nine items to evaluate the symptoms of major depressive disorder according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV). Presence of depression is defined as two or more depressive symptoms, with at least one being depressed mood or anhedonia.
Subjective symptoms
The symptoms subscale of the M.D. Anderson Symptoms Inventory (MDASI) includes 13 items describing the patient's symptoms during the last 24 h, from 0 (not at all) to 10 (as bad as you can imagine) (25, 26) . Pain, fatigue, shortness of breath and difficulty remembering were the items used in this study. The first three symptoms were chosen because these are one of the highly prevalent in cancer population (27) . We used difficulty remembering item as a subjective assessment of cognitive dysfunction. The rest of items were not included in analysis to avoid the multicollinearity.
Medical and demographic information
Information on the diagnosis and stage of cancer and Eastern Cooperative Oncology Group performance status score was obtained from attending physicians. Information on age, sex, educational attainment, job and household size was obtained from patients.
Statistical analysis
We estimated the frequency of cognitive dysfunction based on MMSE scores and calculated 95% confidential intervals (CIs). To explore the clinical indicators of cognitive dysfunction, participants were divided into two groups according to the presence of cognitive dysfunction. We decided that possible clinical indicators should be chosen from information routinely evaluated in clinical oncology practice. First, univariate analyses were conducted to investigate the association between cognitive dysfunction and the investigated factors using the chi-square test and/or Fisher's exact test, as appropriate. Variables with a P value of <0.10 in univariate analyses were entered as independent variables in a logistic regression analysis.
The predictors of cognitive dysfunction were examined among patients without cognitive dysfunction at T1. The dependent variable was new-onset cognitive dysfunction at T2. The same set of possible independent variables described above was included in this analysis, and predictors were investigated using the same statistical methods as were used to identify clinical indicators.
Receiver operating characteristic analysis was conducted to examine how well the factors identified in this study actually predicted new-onset cognitive dysfunction. Area under the curve (AUC) was calculated as an indicator of the accuracy of the prediction model. In general, an AUC score of 0.8 or greater indicates sufficient discrimination ability (28) . The positive predictive value (PPV) and negative predictive value were also calculated to address the usefulness of the test in clinical practice.
A P value of less than 0.05 was adopted as the significance level in all statistical analyses, and all P values reported were two-tailed. We used statistical analysis software SPSS version 22 for Windows for all statistical analyses.
Results
Patient characteristics
During the investigation period, a total of 223 potential participants were identified for the study. We excluded 41 patients for ineligibility (21 with serious physical condition, nine with serious mental condition, nine with cognitive dysfunction too severe for study participation, and two who did not understand Japanese) and nine patients for logistical reasons. Of the remaining 173 eligible patients, we obtained informed consent from 156 (consent rate 156/173 = 90.2%). Finally, available data were obtained from 145 patients (11 did not complete the survey). Table 1 shows baseline demographic and clinical characteristics of the 145 participants. The mean (±SD) and median age of the study sample were 73.8 (±5.9) and 74 years, respectively.
Frequency of cognitive dysfunction
Of the 145 patients, 29 patients (20%, 95% CI = 14-27%) were judged to have cognitive dysfunction according to MMSE scores.
Clinical indicators of cognitive dysfunction
Results of univariate analyses of the associations between possible indicator variables and cognitive dysfunction at T1 are shown in Table 2 . Education, performance status, ADL, IADL and depression were significant factors in bivariate analysis. Results of the logistic regression analysis are shown in Table 3 . Participants with cognitive dysfunction were significantly more likely to have less educational attainment and to have poorer IADL compared with those without cognitive dysfunction.
Predictors of cognitive function at T2
Among 116 participants without cognitive dysfunction at T1, 99 underwent cognitive assessment at T2. We excluded 17 participants (one with a serious physical condition, one who changed hospitals, one who did not undergo chemotherapy, eight who refused to complete the questionnaire or study, six who failed to complete the survey, and four due to logistical reasons). There was no significant difference in characteristics between patients who participated in the survey at T2 and those who did not. Among 99 patients who did not have cognitive dysfunction at T1 and underwent assessment at T2, 7 (7%, 95% CI = 2-12%) developed new-onset cognitive dysfunction. Results of univariate analyses are shown in Table 4 . Patients who expressed the subjective perception of difficulty remembering on the MDASI were significantly more likely to develop cognitive dysfunction at T2. Logistic regression analysis was not conducted for this purpose because we found only one significant variable associated with cognitive dysfunction. The optimal cut-off point was 1/2 for the 'difficulty in remembering' item, which was associated with 85.7% sensitivity and 75.0% specificity, 20.5% positive-predictive value, 98.6% negative-predictive value, and 10.53 positive likelihood ratio. AUC was 0.81.
Additionally, we conducted post poc analysis to explore which domains of MMSE were deteriorated using paired nonparametric tests, and found significant decrease in the items of 'Attention and Calculation (serial sevens)' (P = 0.02).
Discussion
Our results indicated that approximately one-fifth of elderly patients with newly diagnosed hematologic malignancy before initial chemotherapy had cognitive dysfunction and that patients with lower educational attainment and IADL disturbance were more highly likely to have cognitive dysfunction. In addition, the subjective perception of difficulty remembering was considered to be a useful predictor of subsequent cognitive dysfunction 1 month after starting chemotherapy.
Overlooking the presence of cognitive dysfunction by medical staff has been frequently reported (29) . Our results indicate that cognitive dysfunction is not uncommon in older cancer patients, even prior to starting initial anti-cancer treatments. Several studies conducted in the breast cancer patients not restricted to the elderly found high prevalence of cognitive impairments before starting chemotherapy (30) . These results indicate that our finding can be explained as a consequence of not only age but also cancer itself. Or there may be a possibility that common risk factors for both the development of cancer and mild cognitive impairment associated with aging lead to cognitive dysfunction (31) .
Cognitive function should be carefully assessed, especially in patients with clinical indicators such as less educational experience and IADL at baseline. Lower educational experience may be a relevance of lower cognitive reserve in older patient (32) . Recently, implementation of the CGA in geriatric oncology has been recommended (33, 34, 35) . The CGA is a multidimensional, often interdisciplinary, diagnostic process aimed at determining the medical, psychological, cognitive and functional capabilities of older individuals in order to develop an overall plan for treatment and longterm follow-up. We feel that the CGA provides a good opportunity to assess cognitive function in geriatric oncology practice.
Several previous studies have addressed the influence of chemotherapy on cognitive function among cancer patients, with inconclusive findings. For example, some studies suggested no effect and others found negative effects (31, 36) . In the current study, although a small proportion of patients had cognitive dysfunction at baseline, results indicated that a non-negligible proportion without cognitive dysfunction may develop new-onset cognitive dysfunction a month after starting chemotherapy. This suggests the potentially negative impact of chemotherapy on cognitive function among elderly patients with hematological cancer. But this finding could be associated with other factors (e.g. psychological distress, cognitive reserve and so on). Since the current study investigates the influence of chemotherapy for short duration, further studies are needed to clarify longer impact of chemotherapy among elderly cancer patients. Our findings also suggest that the perceived ability to remember may be affected by chemotherapy, as perceived difficulty remembering was the only significant predictor of subsequent cognitive dysfunction. It is important to note that although sensitivity and specificity levels for the prediction of cognitive dysfunction using this item were sufficient, the positive predictive value was insufficient. This may be partly because PPV depends on the observed marginal prevalence. In any case, evaluating the subjective perception of difficulty remembering before initial chemotherapy may be useful for early detection of chemotherapy-induced cognitive dysfunction.
Additionally, based on the result that 'Serial sevens' of MMSE showed a significant decrease from T1 to T2, we consider we can plan of clinical intervention on capacity of calculation might be beneficial for prevention of chemotherapy-induced cognitive dysfunction.
This study had several strengths in comparison with existing studies. First, it longitudinally examined cognitive dysfunction in older hematologic cancer patients. The impact of chemotherapy on cognition in older patients with cancer may be more significant given the higher prevalence of pre-existing cognitive dysfunction in this age group, however, other previous studies often do not include enough older patients with cancer to evaluate the interactions that exist among cancer, aging and effects on cognition (37) . Second, patients were consecutively recruited, and the attrition rate was minimal. However, although it was ethically inevitable to avoid, the fact that nine patients with cognitive dysfunction were unable to participate led to an underestimation of the frequency of cognitive dysfunction. Third, comprehensive geriatric assessments were conducted using internationally validated measures.
Some methodological limitations also deserve mention. First, we assessed cognitive dysfunction using the MMSE. Although it is the most frequently utilized tool to assess cognitive function, it cannot detect 'caseness' (the degree to which the accepted standardized diagnostic criteria for the condition is applicable to the patient). Also MMSE is not a sensitive measure that allows for the evaluation of subtle cognitive change. In addition, we did not investigate the diagnoses of dementia or delirium. Because we conducted the assessment at T1 just after letting them know the cancer diagnosis, we considered it was highly important to lessen the burden on patients. Second, the duration between T1 and T2 might have been too short to detect a change in cognitive dysfunction before vs. after starting chemotherapy. As a result, the rate of new onset cases was small, and the statistical power was believed to be insufficient. Third, we did not take individual chemotherapy regimens into account when exploring the predictors of cognitive dysfunction due to the wide variation in chemotherapy treatments. In addition, the fact that this study was conducted at a single institution in Japan may have introduced institution bias. Fourth, there was a possibility that the sample size of patients with cognitive dysfunction at T1 was only 29, not enough to perform logistic regression analysis. Finally, attention should be paid when generalizing the results of this study to other populations, especially patients with solid carcinomas.
In conclusion, cognitive dysfunction is common in newly diagnosed older patients with hematological malignancy. Medical staff should routinely assess this issue before starting treatment, especially in patients who have clinical indicators. In addition, even if patients do not have cognitive dysfunction at baseline, those who report forgetfulness should be closely monitored. Early detection of cognitive dysfunction enables physicians to plan individual support for patients and to maximize patient autonomy.
